BrainStorm claims PhIIa ALS success; Amunix inks development deal with Naia;

@FierceBiotech: Aduro bags $51M for its 'breakthrough' cancer combo. Story | Follow @FierceBiotech

@JohnCFierce: Big round of deals today augurs well for new partnerships/ M&A in 2015. #JPM15 will be abuzz with deal talk (not unusual). #biotech | Follow @JohnCFierce

@DamianFierce: $AMGN buys into CAR-T with $KITE partnership. Release | Follow @DamianFierce

> Shares of BrainStorm Cell Therapeutics ($BCLI) shot up on Friday in anticipation of positive data from a small Phase IIa study of NurOwn in amyotrophic lateral sclerosis (ALS). A total of 14 patients were involved and investigators said that they tracked a slower progression of the disease following treatment. Shares dropped 20% on Monday morning after the biotech released the data and investors got a chance to cash in on some fast money. Release

> Amunix and Naia signed two licenses to further develop two Amunix receptor agonist product candidates: GLP-1-XTEN, a glucagon-like peptide-1 receptor agonist for the treatment of Type 2 diabetes and GLP-2-XTEN, a glucagon-like peptide-2 receptor agonist for the treatment of short bowel syndrome. Amunix has the chance to earn up to $70 million in milestones for each project. Release

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Aethlon Medical snagged FDA approval for clinical trial of bio-filtration device to treat Ebola. Release | Follow @EmilyWFierce

> FDA deems Halyard's recalled KimVent endotracheal tubes potentially deadly. News

> Survey: Most U.S. consumers eager to use wearable devices to monitor their health. Report

Pharma News

@FiercePharma: Pfizer's growth spurt continues with pickup of Switzerland's Redvax. FierceVaccines Story | Follow @FiercePharma

@CarlyHFierce: Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Story | Follow @CarlyHFierce

> Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon. Article

> Pfizer pads growing vaccines unit with CMV pickup. Item

> Merck poised for early Keytruda launch in lung cancer, analyst says. Article

Biotech IT News

> Scripps director: Validation needed to unlock the potential of wearables. Item

> NHS England picks 100,000 Genomes Project sites ahead of February start date. Article

> Analytics and Big Data investments spur bumper year for digital health funding. Story

> FDA outlines industry-focused ambitions as Mini-Sentinel graduates. More

> Roche buys Bina to add informatics piece to its genomics resurgence. News

CRO News

> Evotec teams up with Ohio State on a new cancer drug. Story

> WuXi goes mobile with a chemistry app. News

> GVK feels the sting after data scandal. More

> Covance could face fines over animal deaths. Story

> PPD bets on Japan with new joint venture. Article

Animal Health News

> Lilly closes Novartis deal, creating second-largest animal health giant. News

> FDA trusts vets to curb antibiotic use, but are ties to drug companies too tight? More

> High debt, low starting salaries plague new veterinarians. Item

> Colorado State nabs record $42.5M gift for translational research institute. Story

> Putney CEO Hoffman sets sights high for 'largest pipeline' in animal health. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.